




Total Synthesis of Phenazinomycin and Its Enantiomer via High-Pressure Reaction

Yoshiharu Kinoshita and Takeshi Kitahara*

Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences,
The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113, Japan.

Abstract: Total synthesis of phenazinomycin, a rare type of phenazine antibiotic, was achieved by using high pressure reaction. Chiral sesquiterpene moiety in the side chain was synthesized employing (*S*)-3-hydroxy-2,2-dimethylcyclohexanone as a chiral source. © 1997 Elsevier Science Ltd.


Phenazinomycin **1** was isolated from the cultural mycelium of *Streptomyces* sp. WK-2057 by Omura and co-workers, and its absolute configuration was also determined by comparing the degradation product of **1** with that of trixagol **2**, a naturally occurring diterpenoid.^{1, 2} This substance possesses antitumor activity against experimental murine tumors *in vivo*, cytotoxic activity against adriamycin-resistant P388 leukemia cells and so on.¹ So far, various types of phenazine antibiotics were isolated as biologically active compounds, but most of them were *C*-substituted ones except a few examples such as **1** and lavanducyanin³ (WS-9659⁴).



We were interested in their unique structures which comprise a 5-*N*-alkylated phenazin-1-one moiety and accomplished construction of the skeleton *via* a high-pressure reaction as shown in our earlier paper.⁵ Herein we report enantioselective synthesis of **1** and its enantiomer *via* a similar strategy.

At first, to obtain optically active allylic alcohol **10**, we prepared hydroxy esters (*1R,3S*)-**4** and (*1S,3S*)-**4** from hydroxy ketone **3** (97.3% ee)⁶ as reported by Suzuki and Mori.⁷ We then executed experiments with (*1S,3S*)-**4** to establish the synthetic route to **10**. The hydroxy ester (*1S,3S*)-**4** was converted to enyne (*S*)-**6** through tosylate (*S*)-**5** by the Tamura and Mori method.⁸ Next, it was necessary to elongate the carbon chain. We initially attempted the C3 extension and treated (*S*)-**5** with $\text{LiC}\equiv\text{CCH}_2\text{OTHP}$, followed by *p*-TsOH in methanol. But we could not separate the desired product from a by-product originated from dihydro-**5**.⁸ So we


employed a stepwise C2+C1 process and, thus, reaction of lithium acetylide of (*S*)-**6** with methyl chloroformate gave (*S*)-**7** in good yield. Addition of thiophenoxide to (*S*)-**7**, followed by treating with MeMgI in the presence of CuI in THF afforded the desired (*Z*)-olefin (*S*)-**8**.⁹ Finally, the desired allylic alcohol (*S*)-**10** was obtained by DIBAL reduction. Similarly, (*1R,3S*)-**4** was converted to allylic alcohol (*R*)-**10**.




Reagents and Conditions

- a) *n*-BuLi / THF ; ClCO₂Me, -70°C (*R*: 80%, *S*: 96%), b) PhSH, NaOH / MeOH, ice-cooled
 c) MeMgI-CuI / THF, -70°C (*R*: 53%, *S*: 66% from **7**), d) DIBAL / toluene, ice-cooled (*R*: 90%
S: 82%), e) *n*-BuLi, Ph₃CH / THF-HMPA ; TsCl ; LiBr, ice-cooled.

In our efforts to construct this rare type of compound, we attempted the reaction (see the scheme shown below) under various condition, and geranylated adduct **12** and farnesylated adduct **13** were obtained only under high-pressure condition in 20% and 11% yield, respectively.¹⁰



It was thus ascertained that a high-pressure reaction was applicable to higher homologues of alkyl halide. Indeed, high-pressure reaction of allylic bromide **11**, obtained from **10** by the method of Stork *et al.*,¹¹ with 1-triethylsilyloxyphenazine **14**⁵ in freshly distilled CH₂Cl₂ (12 kbar for **1**, 14 kbar for *ent*-**1**, 23h, rt) gave ammonium salt which, without isolation, was treated with tris(dimethylaminosulfur) (trimethylsilyl)difluoride (TASF)⁵ to afford phenazinomycin **1** [20% from (*R*)-**10**] or *ent*-**1** [20% from (*S*)-**10**]. Synthetic phenazinomycin **1** was identical to the natural product in all respects.^{12, 13}



Reagent and Conditions

high pressure (*R*: 12 kbar, *S*: 14 kbar) / CH₂Cl₂, rt ; TASf / CH₂Cl₂, rt (*R*: 20%, *S*: 20% from **10**)

In conclusion, we accomplished the synthesis of both enantiomers of phenazinomycin, an antitumor 5-*N*-alkylphenazinone antibiotic, via simple *N*-alkylation under a high-pressure condition. Synthesis of various types of *N*-alkylphenazinones via this efficient process is in progress and the details, including the synthesis of lavanducyanin and phenazinomycin, will be soon reported in a full account. Biological activities of all these analogues are now under investigation and will be reported elsewhere.



Acknowledgments

We thank Prof. S. Ohmura, The Kitasato Institute, and School of Pharmaceutical Sciences, Kitasato University, for the generous gift of spectral data of phenazinomycin. Our thanks are due to Dr. T. Nakata, Dr. K. Nagasawa and Mr. H. Ohmori, The Institute of Physical and Chemical Research (RIKEN) for the use of high-pressure reaction apparatus. This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Culture and Sports, Japan.

References and Notes

- Funayama, S.; Eda, S.; Komiyama, K.; Ohmura, S.; Tokunaga, T. *Tetrahedron Lett.*, **1989**, *30*, 3151-3154.
 - Ohmura, S.; Eda, S.; Funayama, S.; Komiyama, K.; Takahashi, Y.; Woodruff, H. B. *J. Antibiotics*, **1989**, *30*, 1037-1042.
- de Pascual Teresa J.; Caballero, E.; Caballero, C.; Medarde, M.; Barrero, A. F.; Grande, M. *Tetrahedron Lett.*, **1978**, *19*, 3491-3494.
- Imai, S.; Furihata, K.; Hayakawa, H.; Noguchi, T.; Seto, H. *J. Antibiotics*, **1989**, *42*, 1196-1198.
- Nakayama, O.; Yagi, M.; Tanaka, M.; Kiyoto, S.; Okuhara, M.; Kosaka, M. *J. Antibiotics*, **1989**, *42*, 1221-1229.
 - Nakayama, O.; Shigematsu, N.; Katayama, A.; Takase, S.; Kiyoto, S.; Hashimoto, M.; Kosaka, M. *J. Antibiotics*, **1989**, *42*, 1230-1240.
- Kinoshita, Y.; Watanabe, H.; Kitahara, T.; Mori, K. *Synlett*, **1995**, 186-188.
- Mori, K.; Mori, H. *Tetrahedron*, **1985**, *41*, 5487-5493.
- Mori, K.; Suzuki, N. *Liebigs Ann. Chem.*, **1990**, 287-292.
- Mori, K.; Tamura, H. *Liebigs Ann. Chem.*, **1990**, 361-368.
- Kobayashi, S.; Mukaiyama, T. *Chem. Lett.*, **1974**, 705-708.
 - Kobayashi, S.; Mukaiyama, T. *Chem. Lett.*, **1974**, 1425-1428.
 - Mukaiyama, T.; Toda, H.; Kobayashi, S. *Chem. Lett.*, **1975**, 535-536.
 - Mori, K.; Mori, H. *Tetrahedron*, **1987**, *43*, 4097-4106.

10. The structures of geranyl derivative **12** and *trans, trans*-farnesyl derivative **13** are shown below.

**12****13**

11. Stork, G.; Grieco, P. A.; Gregson, M. *Tetrahedron*, **1969**, *18*, 1393-1395.

12. Signals of ^1H on phenazine skeletal carbons are broadened in CD_3OD .

^1H NMR data of **1**

CD_3OD , 500 MHz δ = 0.78 (3H, s), 0.84 (3H, s), 1.15 (2H, m), 1.44-1.55 (4H, m), 1.65 (1H, m), 1.78-2.12 (4H, m), 2.00 (3H, s), 4.38 (1H, s), 4.65 (1H, s), 5.15 (1H, s), 5.36 (2H, s), 6.44 (1H, d-like), 6.63 (1H, d-like), 7.73 (1H, t-like), 7.94 (2H, d-like), 8.04 (1H, br), 8.38 (1H, br)

CDCl_3 , 500 MHz δ = 0.81 (3H, s), 0.88 (3H, s), 1.18 (1H, m), 1.42-1.67 (5H, m), 1.82-2.10 (5H, m), 1.94 (3H, s), 4.46 (1H, d, J = 2.4 Hz), 4.71 (1H, t-like), 4.90 (2H, d, J = 5.5 Hz), 5.11 (1H, td-like), 5.85 (1H, d, J = 7.6 Hz), 6.56 (1H, dd, J = 9.5, 0.9 Hz), 7.42 (1H, d, J = 8.5 Hz), 7.47 (1H, ddd, J = 8.2, 7.0, 1.2 Hz), 7.60 (1H, dd, J = 9.5, 7.5 Hz), 7.76 (1H, ddd, J = 8.5, 7.0, 1.5 Hz), 8.36 (1H, dd, J = 8.2, 1.5 Hz)

*lit.*¹ CD_3OD , 300 MHz δ = 0.78 (3H, s), 0.84 (3H, s), 1.28 (2H, m), 1.48 (2H, m), 1.57 (2H, m), 1.65 (1H, m), 1.90 (2H, m), 1.98 (2H, m), 2.00 (3H, s), 4.39 (1H, s), 4.66 (1H, s), 5.14 (1H, t, J = 5.2 Hz), 5.32 (2H, d, J = 5.2 Hz), 6.39 (1H, d, J = 8.4 Hz), 6.59 (1H, d, J = 8.4 Hz), 7.70 (1H, dd, J = 7.8, 7.8 Hz), 7.88 (1H, d, J = 7.8 Hz), 7.90 (1H, dd, J = 8.4, 8.4 Hz), 8.02 (1H, dd, J = 7.8, 7.8 Hz), 8.33 (1H, d, J = 7.8 Hz)

13. IR data of **1**

ν_{max} (KBr) = 2929, 1633, 1502, 1464, 1444, 1244, 1161, 887, 756, 723 cm^{-1}

*lit.*¹ ν_{max} (KBr) = 2938, 1633, 1501, 1467, 1446, 1243, 1159, 887, 755, 723 cm^{-1}

(Received in Japan 21 April 1997; revised 23 May 1997; accepted 30 May 1997)